Harmony Biosciences Holdings Inc.is a pharmaceutical company. It engages in developing and commercializing therapies for rare neurological disorders. Harmony Biosciences Holdings Inc.is based in Plymouth Meeting, Pennsylvania.
| Revenue (Most Recent Fiscal Year) | $868.45M |
| Net Income (Most Recent Fiscal Year) | $158.69M |
| PE Ratio (Current Year Earnings Estimate) | 10.60 |
| PE Ratio (Trailing 12 Months) | 12.96 |
| PEG Ratio (Long Term Growth Estimate) | 0.37 |
| Price to Sales Ratio (Trailing 12 Months) | 2.42 |
| Price to Book Ratio (Most Recent Quarterly Book Value per Share) | 2.31 |
| Price to Cash Ratio (Most Recent Annual Cash Flow per Share) | 12.56 |
| Pre-Tax Margin (Trailing 12 Months) | 25.13% |
| Net Margin (Trailing 12 Months) | 18.88% |
| Return on Equity (Trailing 12 Months) | 20.06% |
| Return on Assets (Trailing 12 Months) | 14.15% |
| Current Ratio (Most Recent Fiscal Quarter) | 3.48 |
| Quick Ratio (Most Recent Fiscal Quarter) | 3.45 |
| Debt to Common Equity (Most Recent Fiscal Quarter) | 0.13 |
| Inventory Turnover (Trailing 12 Months) | 39.51 |
| Book Value per Share (Most Recent Fiscal Quarter) | $17.16 |
| Earnings per Share (Most Recent Fiscal Quarter) | $1.28 |
| Earnings per Share (Most Recent Fiscal Year) | $2.71 |
| Diluted Earnings per Share (Trailing 12 Months) | $3.08 |
| Exchange | NASDAQ |
| Sector | Healthcare |
| Industry | Biotechnology |
| Common Shares Outstanding | 58.24M |
| Free Float | 51.83M |
| Market Capitalization | $2.33B |
| Average Volume (Last 20 Days) | 0.76M |
| Beta (Past 60 Months) | 0.96 |
| Percentage Held By Insiders (Latest Annual Proxy Report) | 11.00% |
| Percentage Held By Institutions (Latest 13F Reports) | 86.23% |
| Annual Dividend (Based on Last Quarter) | $0.00 |
| Dividend Yield (Based on Last Quarter) | 0.00% |